Girentuximab(Synonyms: G250; cG250)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Girentuximab (Synonyms: G250; cG250)

Girentuximab (G250) 是一种嵌合单克隆抗体，可与碳酸酐酶 IX (CAIX) 结合，碳酸酐酶 IX 是一种在透明细胞肾细胞癌 (ccRCC) 中广泛表达的细胞表面糖蛋白。

Girentuximab(Synonyms: G250; cG250)

Girentuximab Chemical Structure

CAS No. : 916138-87-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC)[1].

体外研究
(In Vitro)

Girentuximab is an IgG1 κ light chain chimeric version of a murine monoclonal antibody (mAb) and recognizes the antigen CAIX[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
CAS 号

916138-87-9
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Chamie K, et al. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol. 2017;3(7):913-920.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务